Open Science In Conversation:
"Developing Drugs in the Open: from patients to pharma"
Tuesday, September 22, 2020
12:00 - 1:00PM EDT
Zoom (Registration Required)
Edward Fon, Scientific Director, The Neuro, Canada Research Chair in Parkinson’s Disease | Professor of Department of Neurology and Neurosurgery, McGill University
Kumar Singh Saikatendu, Director at Takeda Pharmaceuticals, Global Research Externalization
How do a patient’s skin cells hold the key to finding new treatments and even cures for devastating neurological diseases?
“What’s unique and exciting is that we are creating the most specific cells for studying disease using the patient’s own tissue, which has distinct advantages over using generic cells or animal models”
- Dr. Edward Fon, Director, The Neuro’s Open Early Drug Discovery Platform (EDDU), The Neuro
The Neuro’s Open Early Drug Discovery Platform (EDDU) leverages breakthroughs in stem cell technology to build a suite of industry-standard assays and discover new patient-centric therapies. Anchored on strategic partnerships with the Structural Genomics Consortium and the Centre for Drug Research and Development, The Neuro’s EDDU has formed agreements with high-level companies like Merck and Thermo-Fisher Scientific. A collaboration with Takeda Pharmaceutical Company is testing compounds to fight Amyotrophic Lateral Sclerosis (ALS), a disease that currently has no cure.
How do you transform patient’s skin cells to study disease? What is a neural organoid and how is it accelerating our understanding of disease and drug discovery? How do we transform and share data with collaborators worldwide to benefit patients? How can academic health institutions openly collaborate with industry to rapidly advance discovery?
Join us for this Open Science in Conversation with a physician and industry partner who will discuss accelerating drug-discovery by transforming patients’ cells and creating unique, open collaborations with researchers world-wide, to drive forward health innovation.